These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 37924960)

  • 1. A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study.
    Qurashi I; Chaudhry IB; Khoso AB; Omair Husain M; Hafeez D; Kiran T; Lane S; Naqvi HA; Minhas FA; Tamizuddin Nizami A; Razzaque B; Qambar Bokhari S; Yung AR; Deakin B; Husain N
    Brain Behav Immun; 2024 Jan; 115():609-616. PubMed ID: 37924960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol.
    Qurashi I; Chaudhry IB; Khoso AB; Farooque S; Lane S; Husain MO; Chu S; Sarginson J; Hamarani M; Naqvi HA; Razzaque B; Minhas FA; Yung AR; Deakin JFW; Husain N
    Trials; 2017 Nov; 18(1):524. PubMed ID: 29121974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.
    Amminger GP; Schäfer MR; Papageorgiou K; Klier CM; Cotton SM; Harrigan SM; Mackinnon A; McGorry PD; Berger GE
    Arch Gen Psychiatry; 2010 Feb; 67(2):146-54. PubMed ID: 20124114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.
    McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EY; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Amminger GP
    JAMA Psychiatry; 2017 Jan; 74(1):19-27. PubMed ID: 27893018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial.
    Deakin B; Suckling J; Barnes TRE; Byrne K; Chaudhry IB; Dazzan P; Drake RJ; Giordano A; Husain N; Jones PB; Joyce E; Knox E; Krynicki C; Lawrie SM; Lewis S; Lisiecka-Ford DM; Nikkheslat N; Pariante CM; Smallman R; Watson A; Williams SCR; Upthegrove R; Dunn G;
    Lancet Psychiatry; 2018 Nov; 5(11):885-894. PubMed ID: 30322824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis.
    Smesny S; Milleit B; Hipler UC; Milleit C; Schäfer MR; Klier CM; Holub M; Holzer I; Berger GE; Otto M; Nenadic I; Berk M; McGorry PD; Sauer H; Amminger GP
    Mol Psychiatry; 2014 Mar; 19(3):317-24. PubMed ID: 23478748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial.
    Rietdijk J; Dragt S; Klaassen R; Ising H; Nieman D; Wunderink L; Delespaul P; Cuijpers P; Linszen D; van der Gaag M
    Trials; 2010 Mar; 11():30. PubMed ID: 20307268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial.
    Andrieu S; Guyonnet S; Coley N; Cantet C; Bonnefoy M; Bordes S; Bories L; Cufi MN; Dantoine T; Dartigues JF; Desclaux F; Gabelle A; Gasnier Y; Pesce A; Sudres K; Touchon J; Robert P; Rouaud O; Legrand P; Payoux P; Caubere JP; Weiner M; Carrié I; Ousset PJ; Vellas B;
    Lancet Neurol; 2017 May; 16(5):377-389. PubMed ID: 28359749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial.
    Lisiecka DM; Suckling J; Barnes TR; Chaudhry IB; Dazzan P; Husain N; Jones PB; Joyce EM; Lawrie SM; Upthegrove R; Deakin B
    Trials; 2015 Mar; 16():71. PubMed ID: 25886254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder?
    Föcking M; Dicker P; Lopez LM; Cannon M; Schäfer MR; McGorry PD; Smesny S; Cotter DR; Amminger GP
    BMC Psychiatry; 2016 Sep; 16(1):326. PubMed ID: 27650124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Social recovery therapy for young people with emerging severe mental illness: the Prodigy RCT.
    Fowler D; Berry C; Hodgekins J; Banerjee R; Barton G; Byrne R; Clarke T; Fraser R; Grant K; Greenwood K; Notley C; Parker S; Shepstone L; Wilson J; French P
    Health Technol Assess; 2021 Nov; 25(70):1-98. PubMed ID: 34842524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial.
    Husain MI; Chaudhry IB; Khoso AB; Husain MO; Hodsoll J; Ansari MA; Naqvi HA; Minhas FA; Carvalho AF; Meyer JH; Deakin B; Mulsant BH; Husain N; Young AH
    Lancet Psychiatry; 2020 Jun; 7(6):515-527. PubMed ID: 32445690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A targeted psychological treatment for sleep problems in young people at ultra-high risk of psychosis in England (SleepWell): a parallel group, single-blind, randomised controlled feasibility trial.
    Waite F; Černis E; Kabir T; Iredale E; Johns L; Maughan D; Diamond R; Seddon R; Williams N; Yu LM; Freeman D;
    Lancet Psychiatry; 2023 Sep; 10(9):706-718. PubMed ID: 37562423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of omega-3 PUFA on immune markers in adolescent individuals at ultra-high risk for psychosis - Results of the randomized controlled Vienna omega-3 study.
    Smesny S; Milleit B; Schaefer MR; Hesse J; Schlögelhofer M; Langbein K; Hipler UC; Berger M; Cotter DR; Sauer H; McGorry PD; Amminger GP
    Schizophr Res; 2017 Oct; 188():110-117. PubMed ID: 28126360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early intervention for psychosis.
    Marshall M; Rathbone J
    Cochrane Database Syst Rev; 2006 Oct; (4):CD004718. PubMed ID: 17054213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.
    Robinson DG; Gallego JA; John M; Hanna LA; Zhang JP; Birnbaum ML; Greenberg J; Naraine M; Peters BD; McNamara RK; Malhotra AK; Szeszko PR
    Schizophr Res; 2019 Feb; 204():295-303. PubMed ID: 30241990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial.
    Morrison AP; French P; Stewart SL; Birchwood M; Fowler D; Gumley AI; Jones PB; Bentall RP; Lewis SW; Murray GK; Patterson P; Brunet K; Conroy J; Parker S; Reilly T; Byrne R; Davies LM; Dunn G
    BMJ; 2012 Apr; 344():e2233. PubMed ID: 22491790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontal delta power associated with negative symptoms in ultra-high risk individuals who transitioned to psychosis.
    Lavoie S; Schäfer MR; Whitford TJ; Benninger F; Feucht M; Klier CM; Yuen HP; Pantelis C; McGorry PD; Amminger GP
    Schizophr Res; 2012 Jul; 138(2-3):206-11. PubMed ID: 22520856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial.
    Bolt LK; Amminger GP; Farhall J; McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Allott KA
    Schizophr Res; 2019 Apr; 206():67-74. PubMed ID: 30558978
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.